Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 91
Filter
1.
Journal of Zhejiang University. Medical sciences ; (6): 185-194, 2023.
Article in English | WPRIM | ID: wpr-982034

ABSTRACT

OBJECTIVES@#To investigate the effects and molecular mechanisms of asiatic acid on β-cell function in type 2 diabetes mellitus (T2DM).@*METHODS@#The T2DM model was established by high fat diet and streptozotocin injection in ICR mice, and the effects of asiatic acid on glucose regulation were investigated in model mice. The islets were isolated from palmitic acid-treated diabetic mice. ELISA was used to detect the glucose-stimulated insulin secretion, tumor necrosis factor (TNF)-α and interleukin (IL)-6. ATP assay was applied to measure ATP production, and Western blotting was used to detect protein expression of mature β cell marker urocortin (Ucn) 3 and mitofusin (Mfn) 2. The regulatory effects of asiatic acid on glucose-stimulated insulin secretion (GSIS) and Ucn3 expression were also investigated after siRNA interference with Mfn2 or treatment with TNF-α.@*RESULTS@#Asiatic acid with the dose of 25 mg·kg-1·d-1 had the best glycemic control in T2DM mice and improved the homeostasis model assessment β index. Asiatic acid increased the expression of Mfn2 and Ucn3 protein and improved the GSIS function of diabetic β cells in vitro and in vivo (both P<0.05). Moreover, it improved the ATP production of islets of T2DM mice in vitro (P<0.05). Interfering Mfn2 with siRNA blocked the up-regulation of Ucn3 and GSIS induced by asiatic acid. Asiatic acid inhibited islet TNF-α content and increased Mfn2 and Ucn3 protein expression inhibited by TNF-α.@*CONCLUSIONS@#Asiatic acid improves β cell insulin secretion function in T2DM mice by maintaining the β cell maturity, which may be related to the TNF-α/Mfn2 pathway.


Subject(s)
Mice , Animals , Insulin Secretion , Diabetes Mellitus, Type 2/drug therapy , Islets of Langerhans/metabolism , Tumor Necrosis Factor-alpha/metabolism , Insulin/therapeutic use , Diabetes Mellitus, Experimental , Mice, Inbred ICR , Glucose/therapeutic use , Interleukin-6/metabolism , RNA, Small Interfering/pharmacology , Adenosine Triphosphate , GTP Phosphohydrolases/therapeutic use
2.
Chinese Journal of Lung Cancer ; (12): 833-842, 2023.
Article in Chinese | WPRIM | ID: wpr-1010091

ABSTRACT

BACKGROUND@#In recent years, immunotherapy represented by programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) immunosuppressants has greatly changed the status of non-small cell lung cancer (NSCLC) treatment. PD-L1 has become an important biomarker for screening NSCLC immunotherapy beneficiaries, but how to easily and accurately detect whether PD-L1 is expressed in NSCLC patients is a difficult problem for clinicians. The aim of this study was to construct a Nomogram prediction model of PD-L1 expression in NSCLC patients based on 18F-fluorodeoxy glucose (18F-FDG) positron emission tomography/conputed tomography (PET/CT) metabolic parameters and to evaluate its predictive value.@*METHODS@#Retrospective collection of 18F-FDG PET/CT metabolic parameters, clinicopathological information and PD-L1 test results of 155 NSCLC patients from Inner Mongolia People's Hospital between September 2016 and July 2021. The patients were divided into the training group (n=117) and the internal validation group (n=38), and another 51 cases of NSCLC patients in our hospital between August 2021 and July 2022 were collected as the external validation group according to the same criteria. Then all of them were categorized according to the results of PD-L1 assay into PD-L1+ group and PD-L1- group. The metabolic parameters and clinicopathological information of patients in the training group were analyzed by univariate and binary Logistic regression, and a Nomogram prediction model was constructed based on the screened independent influencing factors. The effect of the model was evaluated by receiver operating characteristic (ROC) curve, calibration curve and decision curve analysis (DCA) in both the training group and the internal and external validation groups.@*RESULTS@#Binary Logistic regression analysis showed that metabolic tumor volume (MTV), gender and tumor diameter were independent influences on PD-L1 expression. Then a Nomogram prediction model was constructed based on the above independent influences. The ROC curve for the model in the training group shows an area under the curve (AUC) of 0.769 (95%CI: 0.683-0.856) with an optimal cutoff value of 0.538. The AUC was 0.775 (95%CI: 0.614-0.936) in the internal validation group and 0.752 (95%CI: 0.612-0.893) in the external validation group. The calibration curves were tested by the Hosmer-Lemeshow test and showed that the training group (χ2=0.040, P=0.979), the internal validation group (χ2=2.605, P=0.271), and the external validation group (χ2=0.396, P=0.820) were well calibrated. The DCA curves show that the model provides clinical benefit to patients over a wide range of thresholds (training group: 0.00-0.72, internal validation group: 0.00-0.87, external validation group: 0.00-0.66).@*CONCLUSIONS@#The Nomogram prediction model constructed on the basis of 18F-FDG PET/CT metabolic parameters has greater application value in predicting PD-L1 expression in NSCLC patients.


Subject(s)
Humans , Carcinoma, Non-Small-Cell Lung/drug therapy , Positron Emission Tomography Computed Tomography , Lung Neoplasms/drug therapy , Fluorodeoxyglucose F18/therapeutic use , Nomograms , Retrospective Studies , B7-H1 Antigen/metabolism , Glucose/therapeutic use , Positron-Emission Tomography/methods
3.
Arch. pediatr. Urug ; 94(2): e214, 2023. tab
Article in Spanish | LILACS, UY-BNMED, BNUY | ID: biblio-1520114

ABSTRACT

Introducción: la hipoglicemia neonatal es un trastorno metabólico frecuente en neonatos, con mayor incidencia en aquellos con factores de riesgo como ser hijos de madre diabética, pequeño para la edad gestacional y pretérmino tardíos. Material y métodos: se realizó un ensayo analítico aleatorizado, controlado por placebo para evaluar la eficacia de la administración de gel de dextrosa al 40% para la prevención de hipoglicemia neonatal en esta población. Se reclutaron un total de 120 pacientes. Resultados: se encontró una menor incidencia de hipoglicemia neonatal al compararla con la incidencia reportada en la literatura internacional. No se encontraron diferencias estadísticamente significativas en cuanto al número de ingresos a áreas de internación para tratamiento de hipoglicemia ni en la alimentación a pecho directo exclusivo al alta entre los grupos. Conclusiones: el gel de dextrosa al 40% en recién nacidos podría ser un tratamiento alternativo para profilaxis de hipoglicemia en recién nacidos con factores de riesgo.


Introduction: neonatal hypoglycemia is a frequent metabolic disorder in neonates, with a higher incidence in those with risk factors such as being children of diabetic mothers, small for gestational age, and late preterm. Methodology: a randomized, placebo controlled analytic trial was conducted to evaluate the efficacy of 40% dextrose gel administration for the prevention of neonatal hypoglycemia in this population. A total of 120 patients were recruited. Results: a lower incidence of neonatal hypoglycemia was found when compared to the incidence reported in the international literature. No statistically significant differences were found in terms of the number of admissions to inpatient areas for hypoglycemia treatment or exclusive direct breastfeeding at discharge between the groups. Conclusions: 40% dextrose gel in newborns could be an alternative treatment for hypoglycemia prophylaxis in newborns with risk factors.


Introdução: a hipoglicemia neonatal é um disturbio metabólico comum em neonatos, com maior incidencia naqueles que apresentam fatores de risco, tais como filhos de mães diabéticas, pequenos para a idade gestacional e prematuros tardios. Metodologia: foi realizado um ensaio analítico randomizado e controlado por placebo para avaliar a eficácia da administração de gel de dextrose a 40% para prevenção de hipoglicemia neonatal nesta população. Um total de 120 pacientes foram recrutados. Resultados: foi encontrada menor incidência de hipoglicemia neonatal quando comparada com a incidência relatada na literatura internacional. Não foram encontradas diferenças estatisticamente significativas relativas ao número de internações em áreas de internação para tratamento de hipoglicemia ou aleitamento materno direto exclusivo para descarga entre os grupos. Conclusões: o gel de dextrose a 40% em recém nascidos pode ser uma alternativa de tratamento para profilaxia de hipoglicemia em recém nascidos com fatores de risco.


Subject(s)
Humans , Male , Female , Infant, Newborn , Congenital Hyperinsulinism/prevention & control , Glucose/therapeutic use , Double-Blind Method , Risk Factors , Congenital Hyperinsulinism/blood
4.
Journal of Experimental Hematology ; (6): 38-44, 2023.
Article in Chinese | WPRIM | ID: wpr-971099

ABSTRACT

OBJECTIVE@#To investigate the influence and mechanism of atorvastatin on glycolysis of adriamycin resistant acute promyelocytic leukemia (APL) cell line HL-60/ADM.@*METHODS@#HL-60/ADM cells in logarithmic growth phase were treated with different concentrations of atorvastatin, then the cell proliferation activity was measured by CCK-8 assay, the apoptosis was detected by flow cytometry, the glycolytic activity was checked by glucose consumption test, and the protein expressions of PTEN, p-mTOR, PKM2, HK2, P-gp and MRP1 were detected by Western blot. After transfection of PTEN-siRNA into HL-60/ADM cells, the effects of low expression of PTEN on atorvastatin regulating the behaviors of apoptosis and glycolytic metabolism in HL-60/ADM cells were further detected.@*RESULTS@#CCK-8 results showed that atorvastatin could inhibit the proliferation of HL-60/ADM cells in a concentration-dependent and time-dependent manner (r=0.872, r=0.936), and the proliferation activity was inhibited most significantly when treated with 10 μmol/L atorvastatin for 24 h, which was decreased to (32.3±2.18)%. Flow cytometry results showed that atorvastatin induced the apoptosis of HL-60/ADM cells in a concentration-dependent manner (r=0.796), and the apoptosis was induced most notably when treated with 10 μmol/L atorvastatin for 24 h, which reached to (48.78±2.95)%. The results of glucose consumption test showed that atorvastatin significantly inhibited the glycolytic activity of HL-60/ADM cells in a concentration-dependent and time-dependent manner (r=0.915, r=0.748), and this inhibition was most strikingly when treated with 10 μmol/L atorvastatin for 24 h, reducing the relative glucose consumption to (46.53±1.71)%. Western blot indicated that the expressions of p-mTOR, PKM2, HK2, P-gp and MRP1 protein were decreased in a concentration-dependent manner (r=0.737, r=0.695, r=0.829, r=0.781, r=0.632), while the expression of PTEN protein was increased in a concentration-dependent manner (r=0.531), when treated with different concentrations of atorvastatin for 24 h. After PTEN-siRNA transfected into HL-60/ADM cells, it showed that low expression of PTEN had weakened the promoting effect of atorvastatin on apoptosis and inhibitory effect on glycolysis and multidrug resistance.@*CONCLUSION@#Atorvastatin can inhibit the proliferation, glycolysis, and induce apoptosis of HL-60/ADM cells. It may be related to the mechanism of increasing the expression of PTEN, inhibiting mTOR activation, and decreasing the expressions of PKM2 and HK2, thus reverse drug resistance.


Subject(s)
Humans , Atorvastatin/pharmacology , PTEN Phosphohydrolase/pharmacology , Sincalide/metabolism , Drug Resistance, Neoplasm/genetics , TOR Serine-Threonine Kinases/metabolism , Leukemia, Promyelocytic, Acute/drug therapy , Doxorubicin/pharmacology , Apoptosis , RNA, Small Interfering/pharmacology , Glycolysis , Glucose/therapeutic use , Cell Proliferation
5.
China Journal of Chinese Materia Medica ; (24): 5271-5277, 2023.
Article in Chinese | WPRIM | ID: wpr-1008724

ABSTRACT

This study explored the protective effect of astragaloside Ⅳ(AS-Ⅳ) on oxygen-glucose deprivation(OGD)-induced autophagic injury in PC12 cells and its underlying mechanism. An OGD-induced autophagic injury model in vitro was established in PC12 cells. The cells were divided into a normal group, an OGD group, low-, medium-, and high-dose AS-Ⅳ groups, and a positive drug dexmedetomidine(DEX) group. Cell viability was measured using the MTT assay. Transmission electron microscopy was used to observe autophagosomes and autolysosomes, and the MDC staining method was used to assess the fluorescence intensity of autophagosomes. Western blot was conducted to determine the relative expression levels of functional proteins LC3-Ⅱ/LC3-Ⅰ, Beclin1, p-Akt/Akt, p-mTOR/mTOR, and HIF-1α. Compared with the normal group, the OGD group exhibited a significant decrease in cell viability(P<0.01), an increase in autophagosomes(P<0.01), enhanced fluorescence intensity of autophagosomes(P<0.01), up-regulated Beclin1, LC3-Ⅱ/LC3-Ⅰ, and HIF-1α(P<0.05 or P<0.01), and down-regulated p-Akt/Akt and p-mTOR/mTOR(P<0.05 or P<0.01). Compared with the OGD group, the low-and medium-dose AS-Ⅳ groups and the DEX group showed a significant increase in cell viability(P<0.01), decreased autophagosomes(P<0.01), weakened fluorescence intensity of autophagosomes(P<0.01), down-regulated Beclin1, LC3-Ⅱ/LC3-Ⅰ, and HIF-1α(P<0.05 or P<0.01), and up-regulated p-Akt/Akt and p-mTOR/mTOR(P<0.01). AS-Ⅳ at low and medium doses exerted a protective effect against OGD-induced autophagic injury in PC12 cells by activating the Akt/mTOR pathway, subsequently influencing HIF-1α. The high-dose AS-Ⅳ group did not show a statistically significant difference compared with the OGD group. This study provides a certain target reference for the prevention and treatment of OGD-induced cellular autophagic injury by AS-Ⅳ and accumulates laboratory data for the secondary development of Astragali Radix and AS-Ⅳ.


Subject(s)
Rats , Animals , PC12 Cells , Proto-Oncogene Proteins c-akt/genetics , Glucose/therapeutic use , Oxygen/metabolism , Beclin-1/pharmacology , TOR Serine-Threonine Kinases/metabolism , Autophagy , Apoptosis , Reperfusion Injury/drug therapy
6.
Ludovica Pediatr ; 25(2): 37-40, dic.2022.
Article in Spanish | LILACS | ID: biblio-1414372

ABSTRACT

Se presenta el reporte de un caso de miositis aguda en un niño de 4 años de edad con COVID-19. El paciente manifestó fiebre y dolor en ambas pantorrillas. Con sospecha de miositis se realizó análisis de CPK, encontrando valores de 4460 UI/L. Asimismo se realizó hisopado nasofaríngeo para SARS-CoV 2, confirmando la infección. El paciente recibió hiperhidratación, presentando resolución de su cuadro clínico en menos de 5 días


This case report describes a 4 year old child with COVID-19. He presented with fever and pain in both calves. Under the suspicion of myositis a CPK analysis was performed, which showed CPK: 4460 UI/L. Nasopharyngeal RT - PCR was also performed, which was positive. As a treatment, the patient received hyperhydration, achieving full recovery after five days


Subject(s)
Humans , Male , Child, Preschool , COVID-19/complications , Myositis/etiology , Acute Disease , COVID-19/diagnosis , Glucose/therapeutic use , Myositis/diagnosis , Myositis/drug therapy
8.
Arch. argent. pediatr ; 119(6): e610-e615, dic. 2021. tab, ilus
Article in Spanish | LILACS, BINACIS | ID: biblio-1353045

ABSTRACT

La intoxicación por bloqueantes de los canales de calcio es un cuadro poco frecuente en la población pediátrica. Los signos y síntomas pueden progresar de forma rápida y llevar al colapso cardiovascular y muerte. El sostén hemodinámico con inotrópicos y vasopresores no suele ser efectivo. La terapia con insulina y glucosa es un complemento eficaz del tratamiento inicial, que está ampliamente estudiado, y se utiliza en diferentes patologías con compromiso hemodinámico. Se presenta el caso de una paciente pediátrica con antecedente de ingestión de dosis altas de amlodipina con fines suicidas, con descompensación hemodinámica refractaria al tratamiento de soporte inotrópico habitual. A partir del tratamiento con insulina y glucosa, se logró la estabilidad hemodinámica, con evolución favorable de la paciente.


Calcium channel blocker poisoning is a rare condition in the pediatric population. Signs and symptoms can be rapidly progressive and lead to cardiovascular collapse and death. Hemodynamic support with inotropics and vasopressors is usually not effective. The insulin/glucose therapy is an effective complement to the initial treatment, which is widely studied and used in different pathologies with hemodynamic compromise. The case of a pediatric patient with a history of high-dose ingestion of amlodipine for suicidal purposes, with hemodynamic decompensation refractory to usual inotropic support treatment, is presented. From the insulin/glucose treatment, hemodynamic stability was achieved with a favorable evolution


Subject(s)
Humans , Female , Adolescent , Suicide, Attempted , Calcium Channel Blockers/poisoning , Amlodipine/poisoning , Drug Overdose/therapy , Glucose/therapeutic use , Insulin/therapeutic use
9.
Rev. chil. endocrinol. diabetes ; 14(1): 17-20, 2021. tab, ilus
Article in Spanish | LILACS | ID: biblio-1146467

ABSTRACT

Insulinoma es un tumor neuroendocrino que surge de las células ß del páncreas y produce hiperinsulinemia endógena. Son neoplasias raras con una incidencia reportada de 4 casos por millón de habitantes por año. La presentación clínica típicamente cursa con síntomas adrenérgicos y neuroglucopénicos secundarios a hipoglicemia. Requiere estudios de niveles séricos de insulina, pro-insulina y péptido C, además de imágenes diagnosticas que confirmen los hallazgos. La mayoría de los insulinomas son benignos, su sitio primario más común es el páncreas y pueden extirparse quirúrgicamente. Se presenta el caso de un hombre de 36 años con déficit cognitivo leve y episodios de diaforesis con deterioro neurológico hasta convulsiones tónico clónicas generalizadas que curiosamente resolvían con uso doméstico de "panela molida". Se ingresó a urgencias por ataques recurrentes de hipoglicemia severa con requerimiento de altas dosis de dextrosa al 50% por acceso central, hasta confirmación diagnóstica, intervención y resección de tumor neuroendocrino pancreático bien diferenciado (G1 según clasificación OMS) tipo insulinoma en la cola del páncreas.


Insulinoma is a neuroendocrine tumor that arises from the ß cells of the pancreas and produces endogenous hyperinsulinemia. They are rare neoplasms with a reported incidence to 4 cases per million inhabitants per year. The clinical presentation typically presents with adrenergic and neuroglycopenic symptoms secondary to hypoglycemia. It requires studies of serum levels of insulin, pro-insulin and C-peptide, in addition to diagnostic images that confirm the findings. Most insulinomas are benign, their most common primary site is the pancreas, and they can be removed surgically. We present the case of a 36-year-old man with mild cognitive deficits and episodes of diaphoresis with neurological deterioration to generalized clonic tonic seizures that curiously resolved with domestic use of "ground brown sugar". He was admitted to the emergency department due to recurrent attacks of severe hypoglycemia with a high-dose requirement for 50% dextrose through central access, until diagnostic confirmation, intervention, and resection of a welldifferentiated pancreatic neuroendocrine tumor (G1 according to WHO classification) insulinoma in the tail of pancreas.


Subject(s)
Humans , Male , Adult , Pancreatic Neoplasms/diagnosis , Insulinoma/diagnosis , Pancreatic Neoplasms/surgery , Pancreatic Neoplasms/complications , Magnetic Resonance Imaging , Neuroendocrine Tumors , Diagnosis, Differential , Epilepsy/diagnosis , Glucose/therapeutic use , Hyperinsulinism/etiology , Hypoglycemia/etiology , Hypoglycemia/drug therapy , Insulinoma/surgery , Insulinoma/complications
10.
REME rev. min. enferm ; 25: e1392, 2021. tab, graf
Article in English, Portuguese | LILACS, BDENF | ID: biblio-1346848

ABSTRACT

RESUMO O objetivo foi mapear o conhecimento sobre o uso da solução de glicose 25% no alívio da dor de recém-nascidos durante a punção arterial e venosa. Trata-se de uma revisão de escopo. Realizada busca em oito fontes de dados (Cumulative Index to Nursing and Allied Health Literature, Literatura Latino-Americana e do Caribe em Ciências da Saúde, Medical Literature Analysis and Retrieval System Online, SciVerse Scopus, Web of Science, Scientific Electronic Library Online, Cochrane Library, Catálogo de Teses e Dissertações) e em buscador eletrônico no mês de agosto de 2020. Foram selecionados 11 estudos, que corroboram a utilização da glicose 25% como medida não farmacológica para redução da dor em Recém-nascidos, evidenciando seu efeito analgésico a partir da redução da pontuação nas escalas que avaliam a dor. Quanto à utilização, notou-se que a maioria utilizou 2 mL dessa solução, por via oral, dois minutos antes do procedimento. As medidas não farmacológicas são de fácil uso e baixo custo. A glicose 25% é vista como um método padrão-ouro para o alívio da dor de Recém-nascidos. Este estudo possibilitou mais embasamento científico ao mostrar que o uso da solução de glicose 25% é benéfico no alívio da dor de recém-nascidos durante a punção arterial e venosa, principalmente quando associada a outras técnicas. O estudo elucida as ações de saúde para o manejo da dor neonatal e contribui para o fomento da visibilidade e relevância científica ao tema.


RESUMEN El objetivo fue mapear el conocimiento sobre el uso de una solución de glucosa al 25% para el alivio del dolor en recién nacidos durante la punción arterial y venosa. Esta es una revisión del alcance. Se buscaron ocho fuentes de datos (Cumulative Index to Nursing and Allied Health Literature, Latin American and Caribbean Literature in Health Sciences, Medical Literature Analysis and Retrieval System Online, SciVerse Scopus, Web of Science, Scientific Electronic Library Online, Cochrane Library, Tesis y disertaciones Catálogo) y en un buscador electrónico en agosto de 2020. Se seleccionaron once estudios, que corroboran el uso de glucosa al 25% como medida no farmacológica para reducir el dolor en Recién Nacido, mostrando su efecto analgésico a partir de la reducción de puntuaciones en escalas que evalúan el dolor. En cuanto al uso, se notó que la mayoría utilizó 2 mL de esta solución, por vía oral, dos minutos antes del procedimiento. Las medidas no farmacológicas son fáciles de usar y económicas. La glucosa al 25% se considera un método de referencia para el alivio del dolor Recién Nacido. Este estudio proporcionó una base más científica al demostrar que el uso de una solución de glucosa al 25% es beneficioso para aliviar el dolor de los recién nacidos durante la punción arterial y venosa, especialmente cuando se asocia con otras técnicas. El estudio dilucida acciones de salud para el manejo del dolor neonatal y contribuye a promover la visibilidad y relevancia científica del tema.


ABSTRACT The objective was to map knowledge about the use of a 25% glucose solution in pain relief in newborns during arterial and venous puncture. This is a scoping review. It was conducted during August 2020 in eight data sources (Cumulative Index to Nursing and Allied Health Literature, Literatura Latino-Americana e do Caribe em Ciências da Saúde, Medical Literature Analysis and Retrieval System Online, SciVerse Scopus, Web of Science, Scientific Electronic Library Online, Cochrane Library, and Theses and Dissertations Catalog), as well as in an electronic search engine. Eleven studies were selected, which corroborate the use of 25% glucose as a non-pharmacological measure to reduce pain in Newborns, evidencing its analgesic effect from the reduction of the scores in the scales that assess pain. Regarding use, it was noticed that most employed 2 mL of this solution, via oral route, two minutes before the procedure. The non-pharmacological measures are low-cost and easy to use. The 25% glucose solution is seen as a gold-standard method for pain relief in Newborns. This study provided additional scientific basis by showing that the use of a 25% glucose solution is beneficial in relieving pain in newborns during arterial and venous puncture, especially when associated with other techniques. The study elucidates the health actions for the management of neonatal pain and contributes to fostering scientific visibility and relevance regarding the theme.


Subject(s)
Infant, Newborn , Pain Management/methods , Glucose/therapeutic use , Analgesia , Blood Gas Analysis
11.
Chinese Medical Journal ; (24): 2968-2975, 2021.
Article in English | WPRIM | ID: wpr-921191

ABSTRACT

BACKGROUND@#Histidine-tryptophan-ketoglutarate (HTK) is a solution commonly used for organ transplantation. However, there is no certified fixed regimen for on-pump heart surgery in neonates. We aimed to retrospectively evaluate the outcomes related to different HTK dosages and to analyze the safety of high-dosage perfusion.@*METHODS@#A total of 146 neonates who underwent on-pump heart surgery with single-shot HTK perfusion were divided into two groups according to HTK dosages: a standard-dose (SD) group (n = 63, 40 mL/kg 60 mL/kg). Propensity score matching (PSM) was performed to control confounding bias.@*RESULTS@#The SD group had a higher weight (3.7 ± 0.4 vs. 3.4 ± 0.4 kg, P  0.05). The incidences of post-operative complications were not significantly different between the two groups. There were no significant differences in ventilation time, intensive care unit stay, and post-operative hospital stay (P > 0.05). Follow-up echocardiography outcomes at 1 month, 3 to 6 months, and 1 year showed that left ventricular ejection fraction and end-diastolic dimension were comparable between the two groups.@*CONCLUSIONS@#In neonatal on-pump cardiac surgery patients, single-shot HD (>60 mL/kg) HTK perfusion had a comparable heart protection effect and short-term post-operative prognosis as standard dosage perfusion of 40 to 60 mL/kg. Thus, this study provides supporting evidence of the safety of HD HTK perfusion.


Subject(s)
Humans , Infant, Newborn , Glucose/therapeutic use , Histidine , Mannitol , Organ Preservation Solutions , Potassium Chloride/therapeutic use , Prognosis , Retrospective Studies , Stroke Volume , Tryptophan , Ventricular Function, Left
13.
Archiv. med. fam. gen. (En línea) ; 16(2): 4-10, nov 2019. tab, ilus
Article in Spanish | LILACS, InstitutionalDB, BINACIS, UNISALUD | ID: biblio-1343052

ABSTRACT

OBJETIVOS: Describir la evolución de una cohorte de pacientes con sindrome de disfunción dolorosa del trocánter mayor tratados con proloterapia. MÉTODOS: 30 pacientes con dolor crónico recibieron una mediana de 3,5 inyecciones de dextrosa al 12,5% y lidocaina al 0,5% en la entesis de los músculos que se insertan en el trocanter mayor. Fueron evaluados sus cambios en el dolor mediante una escala analógica visual (EAV) y en la calidad de vida, a través del puntaje Euro Quol 5D. RESULTADOS: A los seis meses de la primera inyección se constató una reducción media del dolor de 5,45 (IC 95% 4,55 a 6,34) puntos de la EAV, desde una media basal de 8,01 (5 a 10) a una media a los seis meses de 2,56 (1 a 7); y una mejoría de la calidad de vida desde 0,401 a 0,891 puntos en la escala Euro Quol 5D. No se observaron efectos adversos. CONCLUSIÓN: Los pacientes con sindrome de disfunción dolorosa del trocánter mayor tratados con proloterapia evolucionaron con una reducción en su nivel de dolor y una mejoría en su calidad (AU)


OBJECTIVES: To describe the evolution of a cohort of patients with a major trochanter dysfunction pain syndrome treated with prolotherapy. METHODS: 30 patients with chronic pain received a median of 3.5 injections of 12.5% dextrose and 0.5% lidocaine in the entesis of the muscles that are inserted into the greater trocanter. Their changes in pain were assessed using a visual analogue scale (VAS) and quality of life, through the Euro Quol 5D score. RESULTS: Six months after the first injection, a mean pain reduction of 5.45 (95% CI 4.55 to 6.34) VAS points was observed, from a baseline average of 8.01 (5 to 10 ) to an average of 2.56 (1 to 7) at six-month; and an improvement in the quality of life from 0.401 to 0.891 points on the Euro Quol 5D scale. No adverse effects were observed. CONCLUSION: Patients with major trochanter dysfunction pain syndrome treated with prolotherapy evolved with a reduction in their level of pain and an improvement in their quality of life (AU)


Subject(s)
Humans , Female , Middle Aged , Aged , Femur/drug effects , Prolotherapy , Glucose/therapeutic use , Pain , Hip/pathology
14.
Rev. bras. cir. cardiovasc ; 34(3): 271-278, Jun. 2019. tab, graf
Article in English | LILACS | ID: biblio-1013463

ABSTRACT

Abstract Objective: The goal of the present study was to compare the myocardial protection obtained with histidine-tryptophan-ketoglutarate (HTK) cardioplegic solution (Custodiol®) and with intermittent hypothermic blood solution. Methods: Two homogenous groups of 25 children with acyanotic congenital heart disease who underwent total correction with mean aortic clamping time of 60 minutes were evaluated in this randomized study. Troponin and creatine kinase-MB curves, vasoactive-inotropic score, and left ventricular function were obtained by echocardiogram in each group. The values were correlated and presented through graphs and tables after adequate statistical treatment. Results: It was observed that values of all the studied variables varied over time, but there was no difference between the groups. Conclusion: We conclude that in patients with acyanotic congenital cardiopathies submitted to total surgical correction, mean aortic clamping time around one hour, and cardiopulmonary bypass with moderate hypothermia, the HTK crystalloid cardioplegic solution offers the same myocardial protection as the cold-blood hyperkalemic cardioplegic solution analyzed, according to the variables considered in our study model.


Subject(s)
Humans , Male , Female , Infant, Newborn , Infant , Cardioplegic Solutions/therapeutic use , Heart Defects, Congenital/surgery , Potassium Chloride/therapeutic use , Procaine/therapeutic use , Reference Values , Time Factors , Troponin/analysis , Echocardiography , Double-Blind Method , Prospective Studies , Reproducibility of Results , Analysis of Variance , Ventricular Function, Left , Treatment Outcome , Statistics, Nonparametric , Protective Agents/therapeutic use , Creatine Kinase, MB Form/analysis , Operative Time , Glucose/therapeutic use , Heart Defects, Congenital/physiopathology , Mannitol/therapeutic use
15.
Braz. j. med. biol. res ; 49(6): e5208, 2016. tab
Article in English | LILACS | ID: lil-781416

ABSTRACT

Cardioplegic reperfusion during a long term ischemic period interrupts cardiac surgery and also increases cellular edema due to repeated solution administration. We reviewed the clinical experiences on myocardial protection of a single perfusion with histidine-tryptophan-ketoglutarate (HTK) for high-risk patients with severe pulmonary arterial hypertension associated with complex congenital heart disease. This retrospective study included 101 high-risk patients undergoing arterial switch operation between March 2001 and July 2012. We divided the cohort into two groups: HTK group, myocardial protection was carried out with one single perfusion with HTK solution; and St group, myocardial protection with conventional St. Thomas' crystalloid cardioplegic solution. The duration of cardiopulmonary bypass did not differ between the two groups. The mortality, morbidity, ICU stay, post-operative hospitalization time, and number of transfusions in HTK group were lower than those in St group (P<0.05). Univariate and multivariate analysis showed that HTK is a statistically significant independent predictor of decreased early mortality and morbidity (P<0.05). In conclusion, HTK solution seems to be an effective and safe alternative to St. Thomas' solution for cardioplegic reperfusion in high-risk patients with complex congenital heart disease.


Subject(s)
Humans , Male , Female , Infant , Child, Preschool , Cardioplegic Solutions/therapeutic use , Cardiopulmonary Bypass/methods , Heart Arrest, Induced/methods , Heart Defects, Congenital/surgery , Hypertension, Pulmonary/surgery , Analysis of Variance , Glucose/therapeutic use , Heart Defects, Congenital/mortality , Hypertension, Pulmonary/mortality , Isotonic Solutions/therapeutic use , Kaplan-Meier Estimate , Mannitol/therapeutic use , Perfusion/methods , Potassium Chloride/therapeutic use , Procaine/therapeutic use , Reproducibility of Results , Retrospective Studies , Risk Factors , Severity of Illness Index , Treatment Outcome
16.
Arch. endocrinol. metab. (Online) ; 59(2): 137-140, 04/2015. tab
Article in English | LILACS | ID: lil-746457

ABSTRACT

Objective To compare the occurrence of hypoglycemia during hemodialysis in chronic kidney disease diabetic patients who present different levels of pre-dialysis glycemia both when using dialysis solutions with and without glucose. Subjects and methods Twenty type 2 diabetic patients in maintenance hemodialysis were submitted to three dialysis sessions (at a 7-day interval each) with dialysis solutions without glucose, with glucose at 55 mg/dL, and at 90 mg/dL subsequently. Blood glucose levels were measured immediately pre-dialysis and at 4 moments during the session, and values under 70 mg/dL were considered as hypoglycemia. Results Average pre-dialysis glycemia was lower in those who presented intra-dialytic hypoglycemia than in those who did not, both in glucose-free (140.4 ± 50.7 vs. 277.7 ± 91.0 mg/dL; p = 0.005; 95%CI: 46.4 to 228.1) and in glucose 55 mg/dL (89.5 ± 10.6 vs. 229.7 ± 105.0 mg/dL; p < 0.05; 95%CI: 9.8 to 270.5). In patients with pre-dialysis glycemia under 140 mg/dL, average intradialytic glycemia was significantly lower than pre-dialysis glycemia only when using glucose-free dialysate (p < 0.0001; 95%CI: 29.9 to 56.0 - t-test). Hypoglycemia during dialysis was observed only when using glucose-free or glucose-poor dialysis solutions. Conclusions The use of glucose-free or glucose-poor dialysis solution presents a high risk of intradialytic hypoglycemia in diabetic renal patients, especially in those with presumed better glycemic control. .


Subject(s)
Adult , Aged , Female , Humans , Male , Middle Aged , Blood Glucose/analysis , /therapy , Hemodialysis Solutions/chemistry , Hypoglycemia/diagnosis , Renal Dialysis/adverse effects , Renal Insufficiency, Chronic/drug therapy , Asymptomatic Diseases , /blood , Glucose/therapeutic use , Hypoglycemia/blood , Hypoglycemia/etiology , Risk Factors , Renal Insufficiency, Chronic/complications
17.
Journal of Korean Medical Science ; : 1217-1225, 2014.
Article in English | WPRIM | ID: wpr-140353

ABSTRACT

In a prospective randomized controlled study, the efficacy and safety of a continuous ambulatory peritoneal dialysis (CAPD) technique has been evaluated using one icodextrin-containing and two glucose-containing dialysates a day. Eighty incident CAPD patients were randomized to two groups; GLU group continuously using four glucose-containing dialysates (n=39) and ICO group using one icodextrin-containing and two glucose-containing dialysates (n=41). Variables related to residual renal function (RRF), metabolic and fluid control, dialysis adequacy, and dialysate effluent cancer antigen 125 (CA125) and interleukin 6 (IL-6) levels were measured. The GLU group showed a significant decrease in mean renal urea and creatinine clearance (-Delta1.2+/-2.9 mL/min/1.73 m2, P=0.027) and urine volume (-Delta363.6+/-543.0 mL/day, P=0.001) during 12 months, but the ICO group did not (-Delta0.5+/-2.7 mL/min/1.73 m2, P=0.266; -Delta108.6+/-543.3 mL/day, P=0.246). Peritoneal glucose absorption and dialysate calorie load were significantly lower in the ICO group than the GLU group. The dialysate CA125 and IL-6 levels were significantly higher in the ICO group than the GLU group. Dialysis adequacy, beta2-microglobulin clearance and blood pressure did not differ between the two groups. The CAPD technique using one icodextrin-containing and two glucose-containing dialysates tends to better preserve RRF and is more biocompatible, with similar dialysis adequacy compared to that using four glucose-containing dialysates in incident CAPD patients. [Clincal Trial Registry, ISRCTN23727549]


Subject(s)
Adult , Aged , Female , Humans , Male , Middle Aged , CA-125 Antigen/analysis , Creatinine/urine , Dialysis Solutions/therapeutic use , Glomerular Filtration Rate , Glucans/therapeutic use , Glucose/therapeutic use , Interleukin-6/analysis , Kidney/physiopathology , Kidney Failure, Chronic/therapy , Membrane Proteins/analysis , Peritoneal Dialysis , Peritoneal Dialysis, Continuous Ambulatory , Urea/urine
18.
Journal of Korean Medical Science ; : 1217-1225, 2014.
Article in English | WPRIM | ID: wpr-140352

ABSTRACT

In a prospective randomized controlled study, the efficacy and safety of a continuous ambulatory peritoneal dialysis (CAPD) technique has been evaluated using one icodextrin-containing and two glucose-containing dialysates a day. Eighty incident CAPD patients were randomized to two groups; GLU group continuously using four glucose-containing dialysates (n=39) and ICO group using one icodextrin-containing and two glucose-containing dialysates (n=41). Variables related to residual renal function (RRF), metabolic and fluid control, dialysis adequacy, and dialysate effluent cancer antigen 125 (CA125) and interleukin 6 (IL-6) levels were measured. The GLU group showed a significant decrease in mean renal urea and creatinine clearance (-Delta1.2+/-2.9 mL/min/1.73 m2, P=0.027) and urine volume (-Delta363.6+/-543.0 mL/day, P=0.001) during 12 months, but the ICO group did not (-Delta0.5+/-2.7 mL/min/1.73 m2, P=0.266; -Delta108.6+/-543.3 mL/day, P=0.246). Peritoneal glucose absorption and dialysate calorie load were significantly lower in the ICO group than the GLU group. The dialysate CA125 and IL-6 levels were significantly higher in the ICO group than the GLU group. Dialysis adequacy, beta2-microglobulin clearance and blood pressure did not differ between the two groups. The CAPD technique using one icodextrin-containing and two glucose-containing dialysates tends to better preserve RRF and is more biocompatible, with similar dialysis adequacy compared to that using four glucose-containing dialysates in incident CAPD patients. [Clincal Trial Registry, ISRCTN23727549]


Subject(s)
Adult , Aged , Female , Humans , Male , Middle Aged , CA-125 Antigen/analysis , Creatinine/urine , Dialysis Solutions/therapeutic use , Glomerular Filtration Rate , Glucans/therapeutic use , Glucose/therapeutic use , Interleukin-6/analysis , Kidney/physiopathology , Kidney Failure, Chronic/therapy , Membrane Proteins/analysis , Peritoneal Dialysis , Peritoneal Dialysis, Continuous Ambulatory , Urea/urine
19.
Clinics ; 67(11): 1303-1308, Nov. 2012.
Article in English | LILACS | ID: lil-656722

ABSTRACT

OBJECTIVE: Postsurgical abdominal adhesions are common, serious postoperative complications. The present study compared the usefulness of 4% icodextrin and canola oil in preventing postoperative peritoneal adhesions. METHODS: Twenty-four Wistar albino rats were divided into three groups. Following a laparotomy, a serosal abrasion was made by brushing the cecum, and 3 mL of 0.9% NaCl, 4% icodextrin, or 3 mL of canola oil were intraperitoneally administered for the control, icodextrin, and canola oil groups, respectively. The abdomen was then closed. All of the rats were sacrificed at day 10. Macroscopic, histopathological, and biochemical evaluations were performed. The results were statistically analyzed using Kruskal-Wallis and ANOVA tests. RESULTS: Macroscopic analyses revealed that both canola oil and 4% icodextrin reduced adhesion formation, but the difference was not statistically significant (p = 0.17). The histopathological examinations revealed no significant differences in terms of giant cell, lymphocyte/plasmocyte, neutrophil, ICAM1, or PECAM1 scores. However, both canola oil and 4% icodextrin significantly reduced fibrosis (p = 0.025). In the canola oil group, the histiocytic reactions were significantly increased (p = 0.001), and the hydroxyproline levels were significantly lower than those in the other groups (p = 0.034). CONCLUSIONS: In the present study, canola oil was determined to be superior to 4% icodextrin in lowering hydroxyproline levels and increasing histiocytic reactions. Considering these results, we believe that canola oil is a promising agent for preventing adhesion formation.


Subject(s)
Animals , Female , Rats , Fatty Acids, Monounsaturated/therapeutic use , Glucans/therapeutic use , Glucose/therapeutic use , Peritoneal Diseases/prevention & control , Peritoneum/surgery , Rats, Wistar , Reproducibility of Results , Treatment Outcome , Tissue Adhesions/prevention & control
20.
Acta cir. bras ; 27(10): 702-706, Oct. 2012. ilus, tab
Article in English | LILACS | ID: lil-650559

ABSTRACT

PURPOSE: To evaluate the influence of the anesthetic regimen on anesthetic recovery, survival, and blood glucose levels following a 90% partial hepatectomy in rats. METHODS: Thirty adult male Wistar rats were divided into two groups according to their anesthetic regimens: intraperitoneal ketamine and xylazine or inhaled isoflurane. In order to prevent hypoglycemia, glucose was administered intraperitoneally and glucose (20%) was added to the drinking water. RESULTS: Anesthetic recovery time was longer in the ketamine and xylazine group. The survival rate after 72 hours was lower (log rank=0.0001) in the ketamine and xylazine group (0.0%) than in the isoflurane group (26.7%). The blood glucose after six hours was lower (p=0.017) in the ketamine and xylazine group (63±31.7 mg/dL) than in the isoflurane group (98±21.2 mg/dL). The prolonged anesthesia recovery time associated with ketamine and xylazine decreased the survival rate and blood glucose levels after 90% hepatectomy. CONCLUSION: Isoflurane anesthesia reduced the recovery time and incidence of hypoglycemia and increased the survival rate in the early hours, providing a therapeutic window that is suitable for experimental studies.


OBJETIVO: Avaliar a influência do regime anestésico sobre a recuperação anestésica, a sobrevida em 72 horas e a glicemia após hepatectomia parcial de 90% em ratos. MÉTODOS: Trinta ratos Wistar machos adultos foram distribuídos em dois grupos conforme o regime anestésico: combinação de ketamina e xilazina intraperitoneal ou isoflurano inalatório. Para prevenção de hipoglicemia foi administrada glicose intraperitoneal e adicionado glicose (20%) na água de beber. RESULTADOS: A recuperação anestésica no grupo ketamina e xilazina foi mais prolongada. Durante primeira hora após hepatectomia, nenhum rato anestesiado com ketamina e xilazina despertou. Todos do grupo isoflurano estavam ativos minutos após final da cirurgia. A sobrevida em 72 horas foi menor (Log rank=0,0001) no grupo ketamina e xilazina (0,0%) que no grupo isoflurano (26,7%). Glicemia em 6 horas do grupo ketamina e xilazina (63±31,7 mg/dL) foi menor (p=0,017) que no grupo isoflurano (98 ±21,2 mg/dL). Prolongado tempo de recuperação anestésica com ketamina e xilazina diminuiu sobrevida e glicemia após hepatectomia 90%. CONCLUSÃO: Anestesia com isoflurano reduziu tempo de recuperação e hipoglicemia, além de aumentar a sobrevida nas primeiras horas, possibilitando uma janela terapêutica adequada para estudos experimentais.


Subject(s)
Animals , Male , Rats , Anesthesia/methods , Anesthetics/therapeutic use , Hepatectomy/methods , Isoflurane/therapeutic use , Ketamine/therapeutic use , Xylazine/therapeutic use , Anesthetics, Inhalation/therapeutic use , Blood Glucose/analysis , Blood Glucose/drug effects , Disease Models, Animal , Glucose/therapeutic use , Hypoglycemia/prevention & control , Injections, Intraperitoneal , Rats, Wistar , Survival Analysis , Time Factors
SELECTION OF CITATIONS
SEARCH DETAIL